SUMMARY D-penicillamine is not generally considered to cause hepatic damage. Cholestatic jaundice developed in a patient with rheumatoid arthritis 4 weeks after penicillamine was added to his regimen, and he died in acute renal failure. The probability that penicillamine caused the cholestasis is discussed.
Examination showed a severely jaundiced Cushingoid looking male. Temperature was 37-4°C, pulse rate 92/min, blood pressure 130/80 mmHg. The liver was tender with a total span of 10 cm. The spleen was not palpable. His right wrist and knee showed acute arthritic changes. The rest of the physical examination was negative.
LABORATORY FINDINGS
Hb 10-1 g/dl; leucocytes 2 3 x 109/l with 4 % myelocytes, 2 % band forms, 28 % segmented polymorphonuclears, 14% eosinophils, 10% monocytes, 42% lymphocytes, thrombocytes 528 x 109/l, reticulocytes 14 2%; sedimentation rate 131 mm in one hour; urea, glucose, electrolytes, calcium, phosphorus, serum proteins normal. Bilirubin 39-2 mg/100 ml (670-3 ,umol/l), mostly direct; SGOT 100 units, alkaline phosphatase 20-4 Bessey-Lowry units; prothrombin time 55%. Cholesterol 665 mg/ 100 ml (17-2 mmol/l), fibrinogen 10 g/l, iron 120 ,ug/ 100 ml (21-5 ,umol/l), TIBC 280 ,tg/100 ml (50 ,umol/l) (Fig. 1) . The bile ducts were normal. There were occasional small foci of hepatccellular necrosis (Fig. 2) . Postmortem examination showed a normal biliary system and pancreas. The liver weighed 2000 g, was smooth and greenish yellow. Liver architecture was well preserved. There were numerous mature lymphocytes in the portal spaces. The very high bilirubin level is an unusual finding, but has been described in patients with hepatitis with haemolysis and in patients with alcoholic liver disease complicated by renal failure (Fulop et al., 1971) . Our patient developed renal failure only after the bilirubin reached 88 mg/100 ml (1505 ,imol/l), but he had anaemia (Hb 10-1 g/dl) and reticulocytosis (1422%), which indicate that haemolysis was a contributing factor. The high bilirubin levels in patients with hepatitis and haemolysis have been explained as due to the increased pigment load in patients with impaired excretory capacity due to hepatobiliary disease. This mechanism could explain the high bilirubin in our patient as he did not have hepatocellular damage, but had impaired excretory capacity. (Russel et al., 1971; Iancu, 1972; Rich and Johnson, 1973; Seaman et al., 1974; Wolfe et al., 1974; Garber et al., 1975) , but the patients reported did not develop jaundice. They had raised transaminases, and some raised alkaline phosphatase. Histological findings were compatible with chronic active hepatitis or acute hepatocellular injury but not with cholestasis. The raised enzyme seems to be dose related as many patients had a blood salicylate level of more than 30 mg/100 ml. The only hepatic damage attributed to steroids is fatty infiltration (Klatskin, 1969) , and prednisone is probably the cause of the fatty infiltration of the liver in our patient.
Penicillamine, on the other hand, has only lately been widely used, and this makes it more likely to be the offending drug. Penicillamine is a degradation product of penicillin. Its chemical structure makes it an effective chelator of copper, mercury, zinc, and lead. It has, therefore, been used in Wilson's disease and lead and mercury poisoning, as well as in cystinuria. As these diseases are rare, its use has been limited. Lately, penicillamine has been used in the treatment of rheumatoid arthritis (Multicentre Trial Group, 1973; British Medical Journal, 1973) and other collagen diseases. Adverse reactions to the drug have been known for some time and include fever, rashes, leucopenia, eosinophilia, thrombocytopenia, loss of taste, nausea, and proteinuria (Levine, 1970) . Recently, side effects such as a lupuslike syndrome (Oliver et al., 1972) , a myasthenia-like clinical picture (Bucknall et al., 1975) , and Goodpasture's syndrome (Sternlieb et al., 1975) have been reported. Leading articles listing the complications of penicillamine (British Medical Journal, 1973 Lancet, 1975) have not mentioned jaundice.
Jaundice associated with penicillamine has been described. Walshe (1968) reported a 9-year-old boy with Wilson's disease in whom penicillamine treatment was discontinued as it caused fever, urticaria, abdominal pain, and jaundice. Rau et al. (1972) reported a case of cholestatic jaundice in a patient receiving penicillamine for scleroderma, who developed fever with an itching macular rash after 2 weeks of treatment. Jaundice appeared after a further week. Her bilirubin level was 7-4 mg/100 ml (126-5 pmol/l), SGOT 
